Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors.
Int Clin Psychopharmacol
; 2024 Feb 22.
Article
en En
| MEDLINE
| ID: mdl-38381905
ABSTRACT
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (nâ
=â
98) were offered treatment with m/umPEA 600â
mg twice daily for 3 months. Those accepting m/umPEA therapy (nâ
=â
57) were compared with those who did not (nâ
=â
41), in terms of depression, fatigue, chronic pain and subjective well-being, through validated scales administered pre- and posttreatment. The two groups did not differ in terms of demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID-19 severity and baseline neuropsychiatric status. Patients receiving m/umPEA showed a greater improvement in depression and fatigue (both Pâ
<â
0.05). Conversely, no association was found with changes in chronic pain or subjective well-being. At multivariable logistic regression, m/umPEA predicted neuropsychiatric improvement independently of age, sex and baseline neuropsychiatric status. Worse pretreatment fatigue and subjective well-being identified those who most likely benefited from treatment. In conclusion, despite its retrospective nature, our study suggests that m/umPEA may improve depression and fatigue in COVID-19 survivors, justifying future research in this setting.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Int Clin Psychopharmacol
Asunto de la revista:
PSICOFARMACOLOGIA
Año:
2024
Tipo del documento:
Article